Sökning: AMNE:(Cancer Research.)
> (2010-2014) >
The prognostic valu...
The prognostic value of MARCKS-like 1 in lymph node-negative breast cancer
-
Jonsdottir, Kristin (författare)
-
Zhang, Hui (författare)
-
Jhagroe, Darshni (författare)
-
visa fler...
-
Skaland, Ivar (författare)
-
Slewa, Aida (författare)
-
- Björkblom, Benny (författare)
- The Norwegian Centre for Movement Disorders, Stavanger University Hospital, Stavanger, Norway
-
Coffey, Eleanor T. (författare)
-
Gudlaugsson, Einar (författare)
-
Smaaland, Rune (författare)
-
Janssen, Emiel A. M. (författare)
-
Baak, Jan P. A. (författare)
-
visa färre...
-
(creator_code:org_t)
- 2012-07-08
- 2012
- Engelska.
-
Ingår i: Breast Cancer Research and Treatment. - : Springer. - 0167-6806 .- 1573-7217. ; 135:2, s. 381-390
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- There is a need for new biomarkers to more correctly identify node-negative breast cancer patients with a good or bad prognosis. Myristoylated alanine-rich C kinase substrate like-1 (MARCKSL1) is a membrane-bound protein that is associated with cell spreading, integrin activation and exocytosis. Three hundred and five operable T1,2N0M0 lymph node-negative breast cancer patients (median follow-up time 121 months, range 10–178 months) were evaluated for MARCKSL1 expression by immunohistochemistry and quantitative real-time PCR. The results were compared with classical prognosticators (age, tumor diameter, grade, estrogen receptor, and proliferation), using single (Kaplan–Meier) and multivariate survival analysis (Cox model). Forty-seven patients (15 %) developed distant metastases. With single and multivariate analysis of all features, MARCKSL1 protein expression was the strongest prognosticator (P < 0.001, HR = 5.1, 95 % CI = 2.7–9.8). Patients with high MARCKSL1 expression (n = 23) showed a 44 % survival versus 88 % in patients with low expression at 15-year follow-up. mRNA expression of MARCKSL1 in formalin fixed paraffin-embedded tissue was also prognostic (P = 0.002, HR = 3.6, 95 % CI = 1.5–8.3). However, the prognostic effect of high and low was opposite from the protein expression, i.e., low expression (relative expression ≤ 0.0264, n = 76) showed a 79 % survival versus 92 % in those with high expression of MARCKSL1 mRNA. Multivariate analysis of all features with distant metastases free survival as the end-point showed that the combination of MARCKSL1 protein and phosphohistone H3 (PPH3) has the strongest independent prognostic value. Patients with high expression (≥13) of PPH3 and high MARCKSL1 protein had 45 % survival versus 78 % survival for patients with low MARCKSL1 protein expression and high expression (≥13) of PPH3. In conclusion, MARCKSL1 has strong prognostic value in lymph node-negative breast cancer patients, especially in those with high proliferation.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- Cancer Research
- Oncology
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Jonsdottir, Kris ...
-
Zhang, Hui
-
Jhagroe, Darshni
-
Skaland, Ivar
-
Slewa, Aida
-
Björkblom, Benny
-
visa fler...
-
Coffey, Eleanor ...
-
Gudlaugsson, Ein ...
-
Smaaland, Rune
-
Janssen, Emiel A ...
-
Baak, Jan P. A.
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
Breast Cancer Re ...
- Av lärosätet
-
Umeå universitet